Researchers have identified gene variants that could lead to new treatment targets and a better understanding of rosacea.
Researchers have identified gene variants that suggest a genetic component for rosacea, which could lead to new treatment targets and a better understanding of this incurable skin disease.
In a study published online in the Journal of Investigative Dermatology (March 12, 2015), researchers from Stanford University’s department of dermatology and 23andMe, a personal genetics company, studied data from nearly 23,000 of the genetics company’s clients, including 2,618 rosacea cases. They identified two rosacea-associated single nucleotide polymorphisms (SNPs), one which replicated in another group of 29,481 people, including 3,205 rosacea cases.
The confirmed SNP, rs763035, is inter-genic between HLA-DRA and BTNL2, according to the study’s abstract.
This research also included obtaining skin biopsies from six people with rosacea, which showed evidence of both HLA-DRA and BTNL2 proteins.
“Exploratory immunohistochemical analysis of HLA-DRA and BTNL2 expression in papulopustular rosacea lesions from six individuals, including one with the rs763035 variant, revealed staining in the peri-follicular inflammatory infiltrate of rosacea for both proteins,” according to the study’s abstract. “In addition, three HLA alleles, all MHC class II proteins, were significantly associated with rosacea in the discovery group and confirmed in the replication group….”
Lead author Anne Lynn S. Chang, MD, assistant professor of dermatology at Stanford University School of Medicine, writes in an email to Dermatology Times that the study’s findings could impact dermatologists' care of rosacea patients in two ways.
“If we can eventually show that different variants of rosacea respond to different treatments, we could help patients pick the treatment most likely to work; hence, obviating trial and error and using medications with side effects that are not effective,” she writes. “Two: If there is an association with a condition outside the skin, we might do a screening test for that extracutaneous condition.”